Surgical Septal Myectomy
Treatment for Hypertrophic Cardiomyopathy
Effectiveness
95%
Safety Score
45%
Clinical Trials
13
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
45
DangerousModerateSafe
Treatment Details
Time to Effect
Immediate obstruction relief, symptomatic improvement over weeks to months
Treatment Duration
One-time procedure, lifetime benefit
Evidence Quality
HIGHNumber Needed to Harm (NNH)
12(Treat 12 patients to see 1 additional serious adverse event)
Confidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$500
Side Effect Mgmt:$500
Total Annual:$1,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$75,000/QALY
QALYs Gained
8
Outcome-Based Costs
Cost per Responder
$1,158
Comparison vs Alcohol Septal Ablation
Cost Difference
+$20,000/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Surgical Septal Myectomy Outcomes
for Hypertrophic Cardiomyopathy
Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+95%
Common Side Effects
Post-operative atrial fibrillation
+25%
Complete heart block requiring pacemaker
+8%
Pericardial effusion
+7%
Infection
+3%
Stroke
+1%
Death
+0.5%
Sources:
Active Clinical Trials
4 active trials recruiting for Surgical Septal Myectomy in Hypertrophic Cardiomyopathy
Surgical Septal Myectomy vs Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy
NCT04684290RECRUITINGNA
100 participants
INTERVENTIONAL
Nieuwegein, Netherlands
Started: Jun 30, 2021
Evaluation of Clinical Efficacy and Prognosis in Patients with Hypertrophic Obstructive Cardiomyopathy Through Hemodynamic Modeling Reconstructed by CT
NCT06683872ENROLLING BY INVITATION
200 participants
OBSERVATIONAL
Hangzhou, China
Started: Aug 1, 2024
Efficacy and Safety of Thoracoscopic Morrow Surgery in the Treatment of Hypertrophic Obstructive Cardiomyopathy
NCT06391788RECRUITINGNA
132 participants
INTERVENTIONAL
Beijing, China
Started: Mar 31, 2023
Surgical Treatment of the Patients With Restrictive Phenotype of the Hypertrophic Cardiomyopathy Without LVOT Obstruction
NCT06977646ENROLLING BY INVITATION
50 participants
OBSERVATIONAL
Moscow, Russia
Started: Jun 1, 2025
Completed Clinical Trials
6 completed trials for Surgical Septal Myectomy in Hypertrophic Cardiomyopathy
Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classical Approach
NCT05726799COMPLETED
60 participants
OBSERVATIONAL
Milan, Italy
Started: Oct 5, 2019
Outcomes of Concomitant Bypass Surgery in Septal Myectomy
NCT06354413COMPLETED
320 participants
OBSERVATIONAL
Started: Jan 1, 2009
Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
NCT04603521COMPLETED
325 participants
OBSERVATIONAL
Bethesda, United States
Started: Oct 20, 2020
Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Insufficiency.
NCT02054221COMPLETEDNA
82 participants
INTERVENTIONAL
Novosibirsk, Russia
Started: Oct 1, 2013
Left Ventricular Mass Index Predicts Clinical Outcomes in Patients with Obstructive Hypertrophic Cardiomyopathy Undergoing Septal Myectomy
NCT06609382COMPLETED
490 participants
OBSERVATIONAL
Beijing, China
Started: Jun 1, 2011
Myocardial Bridging in Obstructive Hypertrophic Cardiomyopathy
NCT06598995COMPLETED
968 participants
OBSERVATIONAL
Beijing, China
Started: Jan 1, 2022